Evidence map›Paper›PMID 31075850›Full record

ArticleNutrients2019

3-(4-Hydroxy-3-methoxyphenyl)propionic Acid Produced from 4-Hydroxy-3-methoxycinnamic Acid by Gut Microbiota Improves Host Metabolic Condition in Diet-Induced Obese Mice.

Ryuji Ohue-Kitano, Satsuki Taira, Keita Watanabe, Yuki Masujima, Toru Kuboshima, Junki Miyamoto, Yosuke Nishitani, Hideaki Kawakami, Hiroshige Kuwahara, Ikuo Kimura

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 35 citations in OpenAlex.

  1. Furong Tongmai Capsule Ameliorates Atherosclerosis in ApoEJournal of cellular and molecular medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Ginsenoside Rc ameliorated atherosclerosisFrontiers in pharmacology · 2022
    Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ryuji Ohue-KitanoDepartment of Applied Biological Science, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Fuchu-shi, Tokyo 183-8509, Japan. r-ohue@go.tuat.ac.jp.
Satsuki TairaDepartment of Applied Biological Science, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Fuchu-shi, Tokyo 183-8509, Japan. s183332q@st.go.tuat.ac.jp.
Keita WatanabeDepartment of Applied Biological Science, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Fuchu-shi, Tokyo 183-8509, Japan. s177090s@st.go.tuat.ac.jp.
Yuki MasujimaDepartment of Applied Biological Science, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Fuchu-shi, Tokyo 183-8509, Japan. fu3265@go.tuat.ac.jp.
Toru KuboshimaDepartment of Applied Biological Science, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Fuchu-shi, Tokyo 183-8509, Japan. s170292x@st.go.tuat.ac.jp.
Junki MiyamotoDepartment of Applied Biological Science, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Fuchu-shi, Tokyo 183-8509, Japan. m-junki@go.tuat.ac.jp.
Yosuke NishitaniResearch Center, Maruzen Pharmaceuticals Co., Ltd., Fukuyama, Hiroshima 729-3102, Japan. y-nishitani@maruzenpcy.co.jp.
Hideaki KawakamiResearch Center, Maruzen Pharmaceuticals Co., Ltd., Fukuyama, Hiroshima 729-3102, Japan. h-kawakami@maruzenpcy.co.jp.
Hiroshige KuwaharaResearch Center, Maruzen Pharmaceuticals Co., Ltd., Fukuyama, Hiroshima 729-3102, Japan. h-kuwahara@maruzenpcy.co.jp.
Ikuo KimuraDepartment of Applied Biological Science, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Fuchu-shi, Tokyo 183-8509, Japan. ikimura@cc.tuat.ac.jp.
Tokyo University of Agriculture and Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

4-Hydroxy-3-methoxycinnamic acid (HMCA), a hydroxycinnamic acid derivative, is abundant in fruits and vegetables, including oranges, carrots, rice bran, and coffee beans. Several beneficial effects of HMCA have been reported, including improvement of metabolic abnormalities in animal models and human studies. However, its mitigating effects on high-fat diet (HFD)-induced obesity, and the mechanism underlying these effects, remain to be elucidated. In this study, we demonstrated that dietary HMCA was efficacious against HFD-induced weight gain and hepatic steatosis, and that it improved insulin sensitivity. These metabolic benefits of HMCA were ascribable to 3-(4-hydroxy-3-methoxyphenyl)propionic acid (HMPA) produced by gut microbiota. Moreover, conversion of HMCA into HMPA was attributable to a wide variety of microbes belonging to the phylum Bacteroidetes. We further showed that HMPA modulated gut microbes associated with host metabolic homeostasis by increasing the abundance of organisms belonging to the phylum Bacteroidetes and reducing the abundance of the phylum Firmicutes. Collectively, these results suggest that HMPA derived from HMCA is metabolically beneficial, and regulates hepatic lipid metabolism, insulin sensitivity, and the gut microbial community. Our results provide insights for the development of functional foods and preventive medicines, based on the microbiota of the intestinal environment, for the prevention of metabolic disorders.

Indexed as

DietAnimalsBacillotaBacteroidetesCitrus sinensisCoffeaCoumaric AcidsDaucus carotaDiet, High-FatFatty LiverGastrointestinal MicrobiomeGastrointestinal TractInsulin ResistanceLipid MetabolismLiverMaleCoumaric AcidsPropionates3-(4-hydroxy-3-methoxyphenyl)propionic acid4-hydroxy-3-methoxycinnamic acidgut microbiotahepatic lipid metabolismhigh-fat dietobesity

Identifiers

PMID31075850
PMCPMC6566268
OpenAlexW2944107000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.